Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nevro Corp.
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.
Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.
Abbott won US FDA approval for its Proclaim XR spinal cord stimulator. The device offers lower-dose and recharge-free neurostimulation for patients with chronic pain with a battery life for up to 10 years.
- Implantable Devices
- Other Names / Subsidiaries
- Nevro Medical Limited
- Nevro Medical Pty Ltd.
- Nevro Medical Sarl